Design and baseline characteristics of the Stroke Prevention by Aggressive Reduction in Cholesterol Levels (SPARCL) Study

Henrik Sillesen, Gregory Albers, Irfan Altafullah, Oscar Benavente, Diane Book, Joseph Broderick, Christopher Calder, Alfred S. Callahan, Walter Carlini, Seemant Chaturvedi, Thomas Chippendale, Wayne Clark, Greg Collins, Bruce Coull, Patricia Davis, Thomas Devlin, Arthur R. Dick, Lucy Younger Dirr-Ledbetter, George Dooneief, R. Scott DuffNordeli Estronza, Alejandro Forteza, Michael R. Frankel, James L. Frey, Gary Friday, Jerome Goldstein, Steven Goldstein, Gleen Graham, Wayne Harper, Jonathan Harris, Barry Hendin, David C. Hess, Richard Hinton, Joshua Hollander, Chung Y. Hsu, Richard L. Hughes, Scott Kasner, T. A. Kent, Lance Kim, Howard Kirshner, Marian LaMonte, Kenneth Levin, Richard Libman, Paul McDowell, Francis E. McGee, Brett Meyer, Alireza Minagar, Frederick E. Munschauer, Richard Munson, Marshall Nash, Sean C. Orr, Gerald Ratinov, Virgilio Salanga, Souvik Sen, Scott Silliman, Richard Singer, Don Smith, Herman Sullivan, David Thaler, Gretchen Tietjen, Michael Tuchman, David Uskavitch, Piero Verro, Ralph Vicari, Richard Weinstein, Janet Wilterdink, Richard Zweifler, Michael Beaudry, Robert Cote, Keith Hoyte, Louise Helene Lebrun, John Norris, Daniel Selchen, Ashfaq Shuaib, Denis Simard, David Spence, Philip Teal, Michael Winger, Reinhold Schmidt, Bruno Pramsohler, Christoph Schmidauer, Markku Kaste, Juhani Sivenius, Anna Wagner, Andreas Terent, Pierre Amarenco, Loic Milandre, Francois Chollet, Thomas de Broucker, Thierry Moulin, Etienne Roullet, Didier Leys, Marie Helene Mahagne, Michael Hennerici, W. D. Heiss, Otto Busse, Roman Haberl, L. Harms, C. Diener, G. Hamann, E. Bemd Ringelstein, Nicola Canal, Antonio Capurso, Angelo Mamoli, Lodovico Frattola, Carlo Gandolfo, Umberto Senin, Michele Zito, Keyser de Keyser, The Netherlands, P. J. Koudstaal, J. A. Haas, G. de Jong, Julien Bogousslavsky, Heinrich Mattie, Ralf Baumgartner, R. S. MacWalter, Roelfe Dijkhuizen, Enefioke Ben Ekpo, Philip Bath, Kennedy R. Lees, Jose Ferro, Luis Cunha, Antonio Davalos, Angel Chamorro, Alvarez Sabin, Dolores Jimenez, Jose Ramon Gonzalez, Aida Lago, Jose Egido, Jose Vivancos, Matias Guiu, Geoffrey Dorman, Stephen Davis, David Gilles, Judy Frayne, Denis Crimmins, Simon Dimmit, Gagrath Pradeep Singh, Russell Scott, Neil Edward Anderson, J. Carr, A. K. Kruger, J. Gardiner

Research output: Contribution to journalArticle

156 Scopus citations

Abstract

Evidence suggests that statin therapy reduces the risk of stroke in patients with coronary heart disease (CHD), but its benefit for patients with cerebrovascular disease and no history of CHD remains uncertain. The Stroke Prevention by Aggressive Reduction in Cholesterol Levels (SPARCL) Study is a prospective, multi-centre, double-blind, randomised, placebo-controlled trial designed to evaluate the effects of atorvastatin 80 mg/day in patients who previously experienced a stroke or transient ischaemic attack, but who have no known CHD. A total of 4,732 patients have been enrolled, and the data collection phase of the study is expected to be completed by October 2004. SPARCL is the first study primarily designed to prospectively evaluate the effect of statin treatment in secondary stroke prevention.

Original languageEnglish (US)
Pages (from-to)389-395
Number of pages7
JournalCerebrovascular Diseases
Volume16
Issue number4
DOIs
StatePublished - Jan 1 2003

    Fingerprint

Keywords

  • Atorvastatin
  • Cholesterol
  • Lipid
  • Statin
  • Stroke

ASJC Scopus subject areas

  • Neurology
  • Clinical Neurology
  • Cardiology and Cardiovascular Medicine

Cite this

Sillesen, H., Albers, G., Altafullah, I., Benavente, O., Book, D., Broderick, J., Calder, C., Callahan, A. S., Carlini, W., Chaturvedi, S., Chippendale, T., Clark, W., Collins, G., Coull, B., Davis, P., Devlin, T., Dick, A. R., Dirr-Ledbetter, L. Y., Dooneief, G., ... Gardiner, J. (2003). Design and baseline characteristics of the Stroke Prevention by Aggressive Reduction in Cholesterol Levels (SPARCL) Study. Cerebrovascular Diseases, 16(4), 389-395. https://doi.org/10.1159/000072562